Company profile for Cadrenal Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical-stage biopharmaceutical company focused on advancing the development of our lead drug candidate, tecarfarin, a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. We are committed to bringing this novel therapy to the market to help improve the lives of the thousands of individuals who suffer fr...
We are a clinical-stage biopharmaceutical company focused on advancing the development of our lead drug candidate, tecarfarin, a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. We are committed to bringing this novel therapy to the market to help improve the lives of the thousands of individuals who suffer from this very serious condition. Our mission is to build a company with a foundation of product candidates that significantly improve quality of life and patient outcomes for individuals with cardiorenal diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
822 North A1A Ponte Vedra, FL 32082
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/17/3207020/0/en/Cadrenal-Therapeutics-to-Conduct-Partnering-and-Investor-Meetings-During-the-J-P-Morgan-44th-Annual-Healthcare-Conference-in-San-Francisco-on-January-12-15-2026.html

GLOBENEWSWIRE
17 Dec 2025

https://www.globenewswire.com/news-release/2025/12/11/3203875/0/en/Cadrenal-Therapeutics-Acquires-VLX-1005-a-First-in-Class-Phase-2-12-LOX-Inhibitor-for-Patients-with-Heparin-Induced-Thrombocytopenia-HIT.html

GLOBENEWSWIRE
12 Dec 2025

https://www.pharmiweb.com/press-release/2025-12-12/cadrenals-anticoagulation-platform-is-expanding-in-a-40-billion-market

PHARMIWEB
12 Dec 2025

https://www.pharmiweb.com/press-release/2025-12-12/cadrenals-quiet-expansion-play-is-starting-to-get-loud

PHARMIWEB
12 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3197094/0/en/Cadrenal-Therapeutics-Appoints-Dr-Lee-Golden-to-Board-of-Directors.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/19/3190865/0/en/Cadrenal-Therapeutics-CEO-Quang-X-Pham-Receives-BioFlorida-s-Executive-of-the-Year-Award.html

GLOBENEWSWIRE
19 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty